A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Latest Information Update: 06 Jan 2025
Price :
$35 *
At a glance
- Drugs AMG 193 (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Gastric cancer; Glioma; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Amgen
- 27 Nov 2024 Planned End Date changed from 30 Oct 2027 to 27 Oct 2027.
- 27 Nov 2024 Planned primary completion date changed from 1 May 2026 to 28 Apr 2026.
- 31 Oct 2024 Planned End Date changed from 10 Oct 2027 to 30 Oct 2027.